Huw joins UNITY at Vice President of Portfolio, Alliance, and Project Management where he is responsible for leading strategic project planning and execution within the discovery and development portfolio. Huw has a diverse background in multidisciplinary team leadership that spans a range of discovery and development phases in disease areas of oncology, infectious diseases, cardiovascular, gastrointestinal, inflammation and neurodegeneration.
Huw most recently served as a program director and team leader at Denali Therapeutics overseeing key activities within clinical and discovery stage programs. This work culminated with the nomination, characterization, and evaluation of Denali’s first clinical stage candidate. Prior to Denali, Huw supported multiple IND filings, clinical studies and successful business development partnering activities in the early development program management group at Theravance Biopharma.
Huw started his career as a medicinal chemist at Novartis Emeryville where he was co-inventor on 13 patents. Huw graduated from Imperial College, London with a Masters in Chemistry (Msci, first class with honors) and received his Ph.D. in Synthetic Organic Chemistry in the field of natural product synthesis from the University of Cambridge, UK. He then completed his post-doctoral research fellowship at the University of California, Irvine.